|
Welcome to AMD Update!
It is estimated that 15 million people in the United States have age-related macular degeneration (AMD), with more than 1.75 million having advanced disease (defined as neovascular AMD or geographic atrophy); the number with advanced disease is expected to climb to almost 3 million by the year 2020. AMD is the leading cause of blindness in adults over 55 years of age.
AMD Update is a monthly e-newsletter dedicated to bringing to the ophthalmologist the latest and most useful clinical information and literature reviews on the management of AMD in a quick, easy to review format. The articles are written by a variety of authors in order to draw upon a wealth of expertise.
We hope that you will find the information timely and applicable to your practice, and that you will look forward to each issue.
Ingrid U. Scott, MD, MPH, Editor
We are pleased to have Ingrid U. Scott, MD, MPH as Editor of AMD Update.
Dr. Scott received both her medical degree and her master’s in public health degree from Johns Hopkins University. She completed ophthalmology residency training, fellowship training in vitreoretinal surgery and diseases and chief residency at the Bascom Palmer Eye Institute, University of Miami, where she stayed as Assistant Professor and then Associate Professor with tenure. Dr. Scott is currently Professor of Ophthalmology and Public Health Sciences at Penn State College of Medicine, where she also serves as the Ophthalmology Residency Program Director. Dr. Scott serves as Co-Chair of the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study funded by the National Eye Institute, serves as the Chair of the Ophthalmic Technology Assessment Retina Panel of the American Academy of Ophthalmology, and has authored or co-authored over 200 peer-reviewed articles or book chapters.
Archived Newsletters:
» Issue 01 - Lucentis and Avastin: When to Use Which?
» Issue 02 - The Role of Intravitreal Triamcinolone Acetonide in AMD Management
» Issue 03 - Follow-up of AMD Patients Treated with Anti-VEGF Therapy: How to Monitor and Decide on Retreatment
» Issue 04 - Is There a Place for Combination Therapy in Neovascular AMD?
» Issue 05 - Should Lutein and Other Nutritional Supplements Be Given for the Therapy of Age-Related Macular Degeneration?
» Issue 06 - Monitoring for the Conversion of Dry to Wet Age-Related Macular Degeneration
» Issue 07 - Effect of Early Detection of Neovascular AMD on Visual Outcome
» Issue 08 - The Role of Fluorescein Angiography in AMD Management
» Issue 09 - How Long Should we Treat Patients with Anti-VEGF Therapy for Wet AMD Once the Lesion is Dry?
» Issue 10 - Artificial Vision
» Issue 11 - The Role of Photodynamic Therapy in AMD Management
» Issue 12 - Value-Based Medicine and Interventions for Neovascular Age-Related Macular Degeneration
» Issue 13 - Risk in AMD: Insight from Studies on Environmental Risk Factors, Genotype, and VEGF
» Issue 14 - Intravitreal Anti-VEGF Plus PDT Combination Therapy for Neovascular AMD: A Clinical Perspective
» Issue 15 - New OCT Devices: Implications for AMD Management
» Issue 16 - Triple Therapy in Exudative AMD
» Issue 17 - The Hidden Cost of Avastin AMD Therapy?
» Issue 18 - The Complex Role of Innate Immunity in Ocular Angiogenesis
|
